Venture capital fund · 1 deal
Paris
Every published round Sofinnova Partners took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Myricx Pharma | Seed | 17 Nov 2020 | $8.2m | Lead | Brandon BioCatalyst portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Mon 16 Nov 2020), Brandon BioCatalyst portfolio (Mon 16 Nov 2020) |
Companies Sofinnova Partners has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Myricx Pharma | 17 Nov 2020, Seed | 1 | 1 |
Fund closes reported for Sofinnova Partners, as distinct from the investments it has made.
Companies Sofinnova Partners has backed that another company then bought. An exit for the holding, not a deal Sofinnova Partners did.
Stories naming Sofinnova Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio